SCHEMBL2656669

SCHEMBL2656669

COc1ccc(Cl)cc1-c1cccc2c(N)c3c(nc12)CN(C1CCC1)C3=O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 6/20 0.41
▸ GABRB3 P28472 6/20 0.41
▸ GABRA2 P47869 6/20 0.41
▸ NPY1R P25929 1/20 0.39
▸ NPY5R Q15761 1/20 0.39
▸ CRHR1 P34998 1/20 0.38
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ CNR1 P21554 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ TNF P01375 2/20 0.36
▸ LITAF Q99732 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661253 0.96 NPY1R (0.40) GABRG2GABRB3GABRA2NPY1RNPY5R
SCHEMBL2669562 0.90 GABRG2 (0.51) GABRG2GABRB3GABRA2NPY1RNPY5R
SCHEMBL2660782 0.90 GABRG2 (0.42) GABRG2GABRB3GABRA2NPY1RNPY5R
SCHEMBL2669504 0.90 GABRG2 (0.41) GABRG2GABRB3GABRA2NPY1RNPY5R
SCHEMBL4916106 0.89 NPY1R (0.42) GABRG2GABRB3GABRA2NPY1RNPY5R
SCHEMBL2659973 0.89 GABRG2 (0.49) GABRG2GABRB3GABRA2NPY1RNPY5R
SCHEMBL4913530 0.88 CNR1 (0.36) CRHR1HTR2AHTR2CCNR1MAPT
SCHEMBL2669426 0.87 NPY1R (0.40) GABRG2GABRB3GABRA2NPY1RNPY5R
SCHEMBL13991083 0.87 GABRG2 (0.44) GABRG2GABRB3GABRA2NPY1RNPY5R
SCHEMBL4912799 0.86 GABRG2 (0.49) GABRG2GABRB3GABRA2NPY1RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback